Direxion Daily Semiconductor Bull 3x Shares ETF
SOXL
VanEck Semiconductor ETF
SMH
Direxion Daily Real Estate Bull 3X Shares ETF
DRN
4
The Technology Select Sector SPDR® Fund
XLK
5
ProShares Ultra Real Estate
URE
US Stock MarketDetailed Quotes
Cartesian Therapeutics (RNAC)
- 6.750
- -0.220-3.16%
Close Apr 24 16:00 ET
- 6.750
- 0.0000.00%
Post 20:01 ET
178.94MMarket Cap-1.34P/E (TTM)
7.120High6.710Low118.89KVolume7.050Open6.970Prev Close825.66KTurnover1.74%Turnover RatioLossP/E (Static)26.51MShares15.57052wk High-1.42P/B46.14MFloat Cap5.60052wk Low--Dividend TTM6.84MShs Float728.003Historical High--Div Yield TTM5.88%Range %5.600Historical Low6.945Avg Price1Lot Size
RNAC Stock Chart
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
RNAC Orderflow
Unit: --
RNAC Orderflow Trend
IntradayDayWeekMonth
No Data
Cartesian Therapeutics (RNAC) News
Needham Maintains Cartesian Therapeutics(RNAC.US) With Buy Rating, Maintains Target Price $42
Cartesian Therapeutics Announces New Employment Inducement Grants
Cartesian Therapeutics Announces Board Member Murat Kalayoglu Resignation
RNAC's Descartes-08 Moves Toward Phase 2 in Rare Muscle Disease: What Investors Should Watch
Oppenheimer Maintains Cartesian Therapeutics(RNAC.US) With Hold Rating
Wedbush Maintains Cartesian Therapeutics(RNAC.US) With Buy Rating, Maintains Target Price $38
Cartesian Therapeutics (RNAC) Stock Forum
$Cartesian Therapeutics (RNAC.US)$
Cartesian Therapeutics Announces Strong Efficacy Signal in Phase 2 Trial of Descartes-08 in Patients with SLE and Expansion of Clinical Development into Myositis
Thursday, 13th November at 4:05 pm
100% LLDAS response rate observed in patients with SLE who received Descartes-08 in Phase 2 open-label trial reaching Month 3 follow-up (n=3)
Disease remission reported as DORIS response seen in 2 out of 3 patients reaching Month 3 follow-up (n=3)
Descartes-08 ...
Cartesian Therapeutics Announces Strong Efficacy Signal in Phase 2 Trial of Descartes-08 in Patients with SLE and Expansion of Clinical Development into Myositis
Thursday, 13th November at 4:05 pm
100% LLDAS response rate observed in patients with SLE who received Descartes-08 in Phase 2 open-label trial reaching Month 3 follow-up (n=3)
Disease remission reported as DORIS response seen in 2 out of 3 patients reaching Month 3 follow-up (n=3)
Descartes-08 ...
$Cartesian Therapeutics (RNAC.US)$ Cartesian Therapeutics Announced 12-month Efficacy And Safety Data From Phase 2b Trial Of Descartes-08 In Participants With Generalized Myasthenia Gravis. Participants Dosed With A Single Six-week Course Of Treatment Of Descartes-08 Were Observed To Continue To Experience A Sustained Benefit In Symptoms
After a single course of therapy, Descartes-08-treated participants were observed to sustain deep responses through long-term follow-up, with an average 4....
After a single course of therapy, Descartes-08-treated participants were observed to sustain deep responses through long-term follow-up, with an average 4....
$Cartesian Therapeutics (RNAC.US)$
Cartesian Therapeutics Gets FDA Rare Pediatric Disease Designation for Dermatomyositis Treatment
Cartesian Therapeutics Gets FDA Rare Pediatric Disease Designation for Dermatomyositis Treatment
Read more
Market Insights
Hot Topics Hot Topics
Surf the ETF wave: Master the market with wisdom & ease!
As the financial landscape evolves, ETFs have emerged as a versatile tool for investors seeking to grow wealth, diversify portfolios, and st
102362254
Sep 4, 2024 16:25
Sharing my long-term ETF story
mr_cashcow
Sep 11, 2024 10:30
Low cost ETF is the way to go! September P/L challenge #6 (200words count entry)